121 related articles for article (PubMed ID: 2117485)
1. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of AIDS-causing retroviruses by the manufacturing procedures for human plasma proteins.
Hilfenhaus J; Gregersen JP
Behring Inst Mitt; 1988 Apr; (82):82-93. PubMed ID: 3044347
[TBL] [Abstract][Full Text] [Related]
3. [HIV safety of commercially produced human plasma proteins].
Hilfenhaus J
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():84-8. PubMed ID: 8000262
[TBL] [Abstract][Full Text] [Related]
4. A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus.
Hilfenhaus J; Geiger H; Lemp J; Hung CL
J Biol Stand; 1987 Jul; 15(3):251-63. PubMed ID: 3649341
[TBL] [Abstract][Full Text] [Related]
5. Affinity chromatography to remove viruses during preparation of plasma derivatives.
Lawrence JE
Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
[TBL] [Abstract][Full Text] [Related]
6. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation.
Morgenthaler JJ; Omar A
Dev Biol Stand; 1993; 81():185-90. PubMed ID: 8174802
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of retroviruses in biologicals manufactured for human use.
Hilfenhaus J; Gregersen JP; Müller H; Nowak T; Pranter W
Dev Biol Stand; 1991; 75():159-69. PubMed ID: 1794617
[TBL] [Abstract][Full Text] [Related]
8. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
11. Assessment of needs for plasma for fractionation in Europe.
Burckhardt JJ
Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
[TBL] [Abstract][Full Text] [Related]
12. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
Welch J; Bienek C; Gomperts E; Simmonds P
Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of viruses and safety of stable plasma products.
Morgenthaler JJ
Beitr Infusionsther; 1989; 24():33-9. PubMed ID: 2481546
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
Hilfenhaus J; Nowak T
Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
[TBL] [Abstract][Full Text] [Related]
16. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
17. Fractionation of outdated freeze-dried plasma: a comparative study of cold- and heat-ethanol fractionation procedures.
Schneider W; Wolter D; Shapiro M; McCarty L
Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(1):109-16. PubMed ID: 88384
[TBL] [Abstract][Full Text] [Related]
18. Continuous fractionation of human plasma.
Mitra G; Lundblad J
Biotechnol Bioeng; 1978 Jul; 20(7):1037-44. PubMed ID: 28798
[TBL] [Abstract][Full Text] [Related]
19. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
20. [Plasma donor screening and product safety].
Storch H; Ponsel G; Igel H; Worofka R
Beitr Infusionsther Transfusionsmed; 1997; 34():31-6. PubMed ID: 9417350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
